OSU-CG5, a novel energy restriction mimetic agent, targets human colorectal cancer cells in vitro

Acta Pharmacologica Sinica

Volumn 35, Issue 3, 2014, Pages 394-400

  Arafa, El Shaimaa A ^a,b   Abdelazeem, Ahmed H ^a,b   Arab, Hany H ^a,c   Omar, Hany A ^a,b  

^a TAIF UNIVERSITY   (Saudi Arabia)

^b Beni Suef University   (Egypt)

^c CAIRO UNIVERSITY   (Egypt)

Author keywords

Akt; apoptosis; colorectal cancer; energy restriction mimetic agent; ER stress; glucose uptake; mTOR; OSU CG5; resveratrol; TrCP

Indexed keywords

ANTINEOPLASTIC AGENT; BETA TRANSDUCIN REPEAT CONTAINING PROTEIN; CASPASE 3; CASPASE 7; CYCLIN D1; GLUCOSE REGULATED PROTEIN 78; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; OSU CG 5; OSU CG5; RESVERATROL; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; BIOLOGICAL MARKER; GLUCOSE; OSU-CG5; STILBENE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL ASSAY; CELL PROLIFERATION; CELL STRAIN CACO 2; CELL STRAIN HCT116; CELL VIABILITY; COLORECTAL CANCER; CONTROLLED STUDY; DOWN REGULATION; ENDOPLASMIC RETICULUM STRESS; GLUCOSE INTAKE; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MTT ASSAY; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING; APOPTOSIS; CACO 2 CELL LINE; CELL SURVIVAL; COLORECTAL TUMOR; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECTS; ENERGY METABOLISM; HCT116 CELL LINE; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOLOGICAL MARKERS; CACO-2 CELLS; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOPLASMIC RETICULUM STRESS; ENERGY METABOLISM; GLUCOSE; HCT116 CELLS; HUMANS; SIGNAL TRANSDUCTION; STILBENES; THIAZOLIDINEDIONES;

EID: 84895527819     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2013.183     Document Type: Article

References (34)

1. Omar HA, Berman-Booty L, Weng JR. Energy restriction: Stepping stones towards cancer therapy. Future Oncol 2012; 8: 1503-6.
2. Hursting S, Dunlap S, Ford N, Hursting M, Lashinger L. Calorie restriction and cancer prevention: a mechanistic perspective. Cancer Metab 2013; 1: 1-11
3. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer 2011; 11: 85-95.
4. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008; 7: 11-20.
5. Omar HA, Berman-Booty L, Kulp SK, Chen CS. Energy restriction as an antitumor target. Future Oncol 2010; 6: 1675-9.
6. Thompson HJ, Zhu Z, Jiang W. Dietary energy restriction in breast cancer prevention. J Mammary Gland Biol Neoplasia 2003; 8: 133-42.
7. Jiang W, Zhu Z, Thompson HJ. Dietary energy restriction modulates the activity of AMP-activated protein kinase, Akt, and mammalian target of rapamycin in mammary carcinomas, mammary gland, and liver. Cancer Res 2008; 68: 5492-9.
8. Omar HA, Salama SA, Arafael SA, Weng JR. Antitumor effects of energy restriction-mimetic agents: thiazolidinediones. Biol Chem 2013; 394: 865-70.
9. Wei S, Kulp SK, Chen CS. Energy restriction as an antitumor target of thiazolidinediones. J Biol Chem 2010; 285: 9780-91.
10. Pancione M, Remo A, Colantuoni V. Genetic and epigenetic events generate multiple pathways in colorectal cancer progression. Patholog Res Int 2012; 2012: 509348.
11. Dirx MJ, van den Brandt PA, Goldbohm RA, Lumey LH. Energy restriction early in life and colon carcinoma risk: results of The Netherlands Cohort Study after 7.3 years of follow-up. Cancer 2003; 97: 46-55.
12. Hughes LA, van den Brandt PA, Goldbohm RA, de Goeij AF, de Bruine AP, van Engeland M, et al. Childhood and adolescent energy restriction and subsequent colorectal cancer risk: results from the Netherlands Cohort Study. Int J Epidemiol 2010; 39: 1333-44.
13. Thompson HJ, Zhu Z, Jiang W. Protection against cancer by energy restriction: all experimental approaches are not equal. J Nutr 2002; 132: 1047-9.
14. Omar HA, Sargeant AM, Weng JR, Wang D, Kulp SK, Patel T, et al. Targeting of the Akt-nuclear factor-kappa B signaling network by [1-(4-chloro-3- nitrobenzenesulfonyl)-1H-indol-3-yl]-methanol (OSU-A9), a novel indole-3-carbinol derivative, in a mouse model of hepatocellular carcinoma. Mol Pharmacol 2009; 76: 957-68.
15. Omar HA, Arafa el SA, Salama SA, Arab HH, Wu CH, Weng JR. OSU-A9 inhibits angiogenesis in human umbilical vein endothelial cells via disrupting Akt-NF-κB and MAPK signaling pathways. Toxicol Appl Pharmacol 2013; 272: 616-24.
16. Omar HA, Chou CC, Berman-Booty LD, Ma Y, Hung JH, Wang D, et al. Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma. Hepatology 2011; 53: 1943-58.
17. Chen CH, Huang PH, Chu PC, Chen MC, Chou CC, Wang D, et al. Energy restriction-mimetic agents induce apoptosis in prostate cancer cells in part through epigenetic activation of KLF6 tumor suppressor gene expression. J Biol Chem 2011; 286: 9968-76.
18. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003; 115: 577-90.
19. Rathmell JC, Fox CJ, Plas DR, Hammerman PS, Cinalli RM, Thompson CB. Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival. Mol Cell Biol 2003; 23: 7315-28.
20. Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 2004; 64: 3892-9.
21. Berman-Booty LD, Chu PC, Thomas-Ahner JM, Bolon B, Wang D, Yang T, et al. Suppression of prostate epithelial proliferation and intraprostatic progrowth signaling in transgenic mice by a new energy restriction-mimetic agent. Cancer Prev Res (Phila) 2013; 6: 232-41.
22. Bialkowska AB, Yang VW. High-throughput screening strategies for targeted identification of therapeutic compounds in colorectal cancer. Future Oncol 2012; 8: 259-72.
23. Solier S, Zhang YW, Ballestrero A, Pommier Y, Zoppoli G. DNA damage response pathways and cell cycle checkpoints in colorectal cancer: current concepts and future perspectives for targeted treatment. Curr Cancer Drug Targets 2012; 12: 356-71.
24. Raina K, Agarwal C, Wadhwa R, Serkova NJ, Agarwal R. Energy deprivation by silibinin in colorectal cancer cells: a double-edged sword targeting both apoptotic and autophagic machineries. Autophagy 2013; 9: 697-713.
25. Kritchevsky D. Colorectal cancer: the role of dietary fat and caloric restriction. Mutat Res 1993; 290: 63-70.
26. Macrae FA. Fat and calories in colon and breast cancer: from animal studies to controlled clinical trials. Prev Med 1993; 22: 750-66.
27. Del Follo-Martinez A, Banerjee N, Li X, Safe S, Mertens-Talcott S. Resveratrol and quercetin in combination have anticancer activity in colon cancer cells and repress oncogenic microRNA-27a. Nutr Cancer 2013; 65: 494-504.
28. Park S, Park O. Modulation of cancer cell proliferation by cell survival signal Akt and tumor suppressive energy sensor AMP-activated protein kinase in colon cancer cells treated with resveratrol. Food Sci Biotechnol 2010; 19: 1537-41.
29. Fouad M, Agha A, Merzabani MA, Shouman S. Resveratrol inhibits proliferation, angiogenesis and induces apoptosis in colon cancer cells: Calorie restriction is the force to the cytotoxicity. Hum Exp Toxicol 2013; 32: 1067-80.
30. Saito S, Furuno A, Sakurai J, Sakamoto A, Park HR, Shin-Ya K, et al. Chemical genomics identifies the unfolded protein response as a target for selective cancer cell killing during glucose deprivation. Cancer Res 2009; 69: 4225-34.
31. Blando J, Moore T, Hursting S, Jiang G, Saha A, Beltran L, et al. Dietary energy balance modulates prostate cancer progression in Hi-Myc mice. Cancer Prev Res (Phila) 2011; 4: 2002-14.
32. Wei S, Chuang HC, Tsai WC, Yang HC, Ho SR, Paterson AJ, et al. Thiazolidinediones mimic glucose starvation in facilitating Sp1 degradation through the up-regulation of beta-transducin repeat-containing protein. Mol Pharmacol 2009; 76: 47-57.
33. 2/M cell cycle arrests by the dietary compound 3,3′- diindolylmethane in HT-29 human colon cancer cells. BMC Gastroenterol 2009; 9: 39-50.
34. Zhao Y, Zhang W, Guo Z, Ma F, Wu Y, Bai Y, et al. Inhibition of the transcription factor Sp1 suppresses colon cancer stem cell growth and induces apoptosis in vitro and in nude mouse xenografts. Oncol Rep 2013; 30: 1782-92.